Neoadjuvant Combo Immunotherapy Studied in Resectable Melanoma
![Neoadjuvant Combo Immunotherapy Studied in Resectable Melanoma](https://bloximages.chicago2.vip.townnews.com/lacrossetribune.com/content/tncms/assets/v3/editorial/4/72/4722db01-402a-55ea-9018-249d3081fec5/635c2478b9484.image.jpg?resize=300%2C200)
FRIDAY, Oct. 28, 2022 (HealthDay News) -- For patients with resectable clinical stage III or oligometastatic stage IV melanoma, neoadjuvant relatlimab and nivolumab combination immunotherapy results in a 57 percent pathologic complete response rate, according to a study published online…